PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Several scholars, lawmakers, intelligence agencies, and the members of the public expressed concerns about political violence surrounding the 2024 election. The fears came amidst increasing threats and acts of physical violence targeting public officials and election workers at all levels of government. Trump was identified as a key figure in increasing political violence in the United States both for and against him. Political violence was at its highest since the 1970s, and the most recent violence came from right-wing assailants. Trump increasingly embraced far-right extremism, conspiracy theories such as Q-Anon, and far-right militia movements to a greater extent than any modern American president. Trump also espoused dehumanizing, combative, and violent rhetoric, and promised retribution against his political enemies. Trump played down but refused to rule out violence following the 2024 election, stating "it depends". Trump also suggested using the military against "the enemy from within" on Election Day that he described as "radical left lunatics", Democratic politicians, and those opposed to his candidacy.
In 1925, the CCP's Central Military Department, was renamed the Central Military Commission. It was first led by Zhang Guotao who was replaced by Zhou Enlai in 1926 as head of the CMC. At the time of the First United Front, the CMC was not a unified military command structure but was more of an administrative liaison with other armed communist groups. The CCP founded its military wing on 1 August 1927 during the Nanchang uprising, beginning the Chinese Civil War. Communist elements of the National Revolutionary Army rebelled under the leadership of Zhu De, He Long, Ye Jianying, Zhou Enlai, and other leftist elements of the Kuomintang (KMT) after the Shanghai massacre in 1927. They were then known as the Chinese Workers' and Peasants' Red Army, or simply the Red Army. In 1934 and 1935, the Red Army survived several campaigns led against it by Chiang Kai-Shek's Kuomintang and engaged in the Long March. During the Second Sino-Japanese War from 1937 to 1945, the CCP's military forces were nominally integrated into the National Revolutionary Army of the Republic of China, forming two main units, the Eighth Route Army and the New Fourth Army. During this time, these two military groups primarily employed guerrilla tactics, generally avoiding large-scale battles with the Japanese, and at the same time consolidating by recruiting KMT troops and paramilitary forces behind Japanese lines into their forces.
In biology and biochemistry, the active site is the region of an enzyme where substrate molecules bind and undergo a chemical reaction. The active site consists of amino acid residues that form temporary bonds with the substrate, the binding site, and residues that catalyse a reaction of that substrate, the catalytic site. Although the active site occupies only ~10–20% of the volume of an enzyme, it is the most important part as it directly catalyzes the chemical reaction. It usually consists of three to four amino acids, while other amino acids within the protein are required to maintain the tertiary structure of the enzymes. Each active site is evolved to be optimised to bind a particular substrate and catalyse a particular reaction, resulting in high specificity. This specificity is determined by the arrangement of amino acids within the active site and the structure of the substrates. Sometimes enzymes also need to bind with some cofactors to fulfil their function. The active site is usually a groove or pocket of the enzyme which can be located in a deep tunnel within the enzyme, or between the interfaces of multimeric enzymes. An active site can catalyse a reaction repeatedly as residues are not altered at the end of the reaction (they may change during the reaction, but are regenerated by the end). This process is achieved by lowering the activation energy of the reaction, so more substrates have enough energy to undergo reaction.
Sources: en.wikipedia.org
== History == It was first used in 1795 shortly after the formation of the Orange Order and was the original system put together by the founding members of the Orange Order. The Grand Orange Lodge of Ireland disliked the ritualism and tried to suppress it as early as 1798 however, the main reason for the opposition to the Royal Arch Purple Degree was that many rural Lodges were practising other degrees in addition to the Royal Arch Purple degree and the gentry deemed this as unacceptable and realised the need for a central system of degrees. The Royal Arch Purple degree was practised in secrecy for a period after the Grand Lodge (in Dublin) deemed the degree illegal, however it was kept alive by the Lodges around County Armagh as it was the system of 'travel' closest to the original ritual put together by the founding members of the Orange Order in 1795. The Grand Lodge maintains their position in not recognising the degree to this day although it now, rather grudgingly, recognises the Royal Arch Purple as an official Order. It was re-constituted in 1911, with the explicit intentions of promoting the Reformed Faith, Charity amongst all men and maintaining historic Orangeism. It was granted its Royal title by the Duke of Cumberland, King Ernest Augustus of Hanover, who was the fifth son of King George III, and brother to King George IV and King William IV, whom he succeeded as King of Hanover.
Raw dry buckwheat is 10% water, 72% carbohydrates, 13% protein, and 3% fat (table). In a reference amount of 100 g (3.5 oz), dry buckwheat supplies 343 calories of food energy, and is a rich source (20% or more of the Daily Value, DV) of three B vitamins (riboflavin, niacin, pantothenic acid) and several dietary minerals (table).
== In popular culture == Christine Weick, an American Christian activist and author, created a video that argued that Monster Energy sports drinks are associated with Satan. The November 2014 video was published on YouTube, garnering over 14 million views as of 2024. The viral nature of the video got her an appearance on the Web Redemption segment of Comedy Central's Tosh.0. The energy drink also features prominently as product placement in the video game Death Stranding (2019), in which it restores stamina and can be consumed by the main character in his private room.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.